Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fresh Tracks Therapeutics Inc V.BBI


Primary Symbol: FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.


GREY:FRTX - Post by User

Fresh Tracks Therapeutics Inc > LinkedIn
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Post by RuudinFranceon Jan 05, 2023 9:44am
415 Views
Post# 35204557

LinkedIn

LinkedInjust found a reminder that Garth Braun is eight years with Stage Completions.
There was this request to congratulate him with this milestone.

I did ask as well for some info concerning the company.

Have fun.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities